There are many treatment options for psoriatic arthritis (PsA), and EULAR—The European Alliance of Associations for Rheumatology—recommends a practical and progressive approach to management based on specific manifestations and disease activity. But assessment of treatment outcomes primarily focuses on improvement in the number of affected joints, disregarding their specific locations. Arthritis affects various joints differently, despite systemic inflammatory cues. In people with rheumatoid arthritis, transcriptomic variances identified in synovial fibroblasts from various joint sites have been shown to translate into joint-specific phenotypes with distinct characteristics and responsiveness to cytokines. These Read More